The Thousand Oaks, Calif., biotech said it would invest $1 billion in new process development, bulk manufacturing and fill-and-finish facilities in Cork, Ireland. The company said it will also expand R&D operations in Cambridge, Mass., San Francisco, Seattle and Cambridge, U.K., and build a new development center in Uxbridge, U.K.
Amgen will move its European headquarters to Zug, Switzerland, from Lucerne, and rename its overseas operations Amgen International.
"Amgen is pleased to establish a site in Ireland as part of our ongoing global development and manufacturing expansion," said Fabrizio Bonanni, senior vice president, Manufacturing. "As demand for our products grows in Europe, Amgen requires capacity closer to this important market."
Amgen anticipates that it will break ground on the Cork projects later this year. It expects to begin operating in Cork in 2009.
On the R&D front, Amgen anticipates future expansion in Japan, Australia, Canada and other locations.
"This significant, long-term investment in our global R&D infrastructure underscores the commitment of Amgen to be the world's best human therapeutics company," said Roger M. Perlmutter, executive vice president, Research and Development. "In particular, our growth in clinical development at Amgen San Francisco and Uxbridge, U.K. will provide the capability to deliver on the promise of our extraordinary pipeline."
The newly formed Amgen International oversees operations in Europe, Australia and the Middle East. Amgen expects that it soon will start up activities in Russia, Mexico and Brazil. By the end of the decade, Amgen anticipates expansion of its commercial activities into not-yet covered countries in Eastern Europe, Central and Southeast Asia, Africa and Latin America.